Drugs Xagena
European Commission has granted marketing authorization to Nexavar ( Sorafenib ) tablets for the treatment of patients with advanced renal cell carcinoma who have failed prior Interferon-alpha or Inte ...
The FDA ( Food and Drug Administration ) has approved Nexavar ( Sorafenib ) for use in patients with a form of liver cancer known as hepatocellular carcinoma, when the cancer is inoperable. Nexavar ...
The FDA ( Food and Drug Administration ) has approved Everolimus tablets ( Afinitor ) for the treatment of patients with advanced renal cell carcinoma after failure of treatment with Sunitinib or Sora ...
The FDA ( Food and Drug Administration ) has expanded the approved uses of Nexavar ( Sorafenib ) to treat metastatic differentiated thyroid cancer.Sorafenib works by inhibiting multiple proteins in ca ...
The European Commission ( EC ) has granted marketing authorization for Stivarga ( Regorafenib ) for the treatment of adult patients with hepatocellular carcinoma ( HCC ) who have been previously treat ...
The European Commission ( EC ) has approved Fotivda ( Tivozanib ) for the treatment of adult patients with advanced renal cell carcinoma ( RCC ) in the European Union plus Norway and Iceland. Tivoza ...
The U.S. Food and Drug Administration ( FDA ) has approved Cyramza ( Ramucirumab injection, 10 mg/mL solution ), as a single agent, for the treatment of patients with hepatocellular carcinoma ( HCC ) ...
Opdivo ( Nivolumab ) 1 mg/kg plus Yervoy ( Ipilimumab ) 3 mg/kg ( injections for intravenous use ) was approved by the U.S. Food and Drug Administration ( FDA ) to treat hepatocellular carcinoma ( HCC ...
The FDA ( U.S. Food and Drug Administration ) has approved Tecentriq ( Atezolizumab ) in combination with Avastin ( Bevacizumab ) for the treatment of people with unresectable or metastatic hepatocell ...
The European Commission has approved Tecentriq ( Atezolizumab ) in combination with Avastin ( Bevacizumab ) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma ( ...
The Food and Drug Administration ( FDA ) has approved Tremelimumab ( Imjudo ) in combination with Durvalumab for adult patients with unresectable hepatocellular carcinoma ( uHCC ). Efficacy was eva ...
